

## Retinal Photoreceptor Degeneration Caused by Mutations in Guanylate Cyclase Activating Proteins (GCAPs)

**James B Ames\***

*Department of Chemistry, University of California, Davis, CA, USA*

**\*Corresponding Author:** James B Ames, Department of Chemistry, University of California, Davis, CA, USA.

**Received:** November 11, 2023; **Published:** November 27, 2023

### Abstract

Retinal photoreceptor degenerative diseases such as rod-cone dystrophies are caused by mutations in retinal  $\text{Ca}^{2+}$ -binding proteins (called GCAPs) that weaken their binding to  $\text{Ca}^{2+}$  and cause dysregulation of retinal guanylyl cyclase (RetGC). The enzymatic activity of RetGC is activated by its binding to  $\text{Ca}^{2+}$ -free GCAPs in light-adapted photoreceptors, whereas RetGC is inhibited by its binding to  $\text{Ca}^{2+}$ -bound GCAPs in dark-adapted photoreceptors. This  $\text{Ca}^{2+}$ -dependent regulation of cyclase activity is important for coordinating the recovery phase of visual phototransduction. Mutations in GCAP1 (G86R, Y99C, I143N) that weaken its  $\text{Ca}^{2+}$  binding also cause constitutive activation of RetGC that in turn leads to rod-cone dystrophies. In this mini review, I propose a structural mechanism to explain how GCAPs control the  $\text{Ca}^{2+}$ -dependent activation of RetGC.

**Keywords:** *Guanylyl Cyclase; Cone-Rod Dystrophy; Retina; Phototransduction; GCAP1; RetGC*

### Abbreviations


GCAP: Guanylyl Cyclase Activating Protein; RetGC: Retinal Membrane Guanylyl Cyclase; cGMP: Cyclic Guanosine Monophosphate; KHD: Kinase Homology Domain

### Introduction

Visual phototransduction in photoreceptor rod and cone cells is promoted by light-activated hydrolysis of cGMP catalyzed by phosphodiesterase [1,2] (Figure 1A). The cytosolic cGMP concentration decreases following illumination and promotes the closure of retinal cyclic nucleotide gated channels (CNG channels), which hyperpolarizes the plasma membrane and generates a neural signal [3-5]. When the light stimulus is removed, the light-activated photoreceptor returns to the resting dark state in a process called visual recovery [1,6]. The light-induced depletion of cGMP can be replenished during visual recovery by the rapid re-synthesis of cGMP catalyzed by the enzyme, retinal guanylyl cyclase (RetGC). Light-dependent cyclase activation is triggered by a light-induced drop in cytosolic  $\text{Ca}^{2+}$  concentration in light activated photoreceptor cells [4,7,8] (See figure 1A).

$\text{Ca}^{2+}$ -dependent cyclase activity in photoreceptor cells (Figure 1B) requires a family of  $\text{Ca}^{2+}$  sensor proteins, called guanylyl cyclase activating proteins (GCAP1-7) [7,9,10]. The  $\text{Ca}^{2+}$ -free GCAPs activate RetGC in light activated photoreceptors at low cytosolic  $\text{Ca}^{2+}$  levels below 50 nM [7]. The  $\text{Ca}^{2+}$ -bound GCAPs inhibit RetGC in dark adapted photoreceptors at high cytosolic  $\text{Ca}^{2+}$  levels above 500 nM [11].

Thus, the GCAPs serve as both an accelerator and brake that modulates the RetGC catalytic activity more than 20-fold inside photoreceptor cells [6,12]. Transgenic mice that lack GCAPs revealed decreased light sensitivity of rods in darkness in contrast to increased sensitivity in bright light [13]. Mutations in GCAP1 (G86R, Y99C, I143N) [14-16] that weaken  $Ca^{2+}$  binding also prevent  $Ca^{2+}$ -sensitive activation of RetGC and cause rod-cone dystrophies [15,17,18]. An important unresolved question is to understand how GCAP1 structurally binds to RetGC to promote  $Ca^{2+}$ -dependent conformational changes that switch on cyclase activation [19]. In this mini review, I propose a structural mechanism for how GCAP1 regulates the  $Ca^{2+}$ -dependent cyclase activity of RetGC, which explains why mutations in GCAP1 (G86R, Y99C, I143N) that weaken or disable  $Ca^{2+}$  binding [15,16,20-22] also lead to retinal disease.



**Figure 1:**  $Ca^{2+}$  dependent RetGC activation mediated by GCAP1. (A) Visual excitation pathway in retinal photoreceptor cells.

Light-activated CNG channel closure promotes a drop in cytosolic  $Ca^{2+}$  level (50 nM) that causes  $Ca^{2+}$  dissociation from GCAP1 that in turn switches on  $Ca^{2+}$ -free GCAPs to activate RetGC in light activated photoreceptors.  $Ca^{2+}$ -bound GCAPs inhibit RetGC at much higher  $Ca^{2+}$  levels (500 nM) in dark-adapted photoreceptors. (B) Schematic model of  $Ca^{2+}$ -dependent activation of RetGC by GCAP1. RetGC consists of three cytosolic domains: KHD (cyan), DD (red) and catalytic domain (yellow) that forms a dimer. Inactive RetGC in the absence of GCAP1 (left panel).  $Ca^{2+}$ -free GCAP1 (green) bound to RetGC (middle panel) and  $Ca^{2+}$ -bound GCAP1 (bound  $Ca^{2+}$  as orange circles) bound to RetGC (right panel).

## Discussion

A structural mechanism of the  $Ca^{2+}$ -dependent activation of RetGC is shown in figure 1B. In dark-adapted photoreceptors, the cytosolic  $Ca^{2+}$  concentration is maintained at a high level (~500 nM), because CNG channels are kept open by the binding of cGMP, which allows  $Ca^{2+}$  influx. The GCAP1 protein is bound to  $Ca^{2+}$  in dark-adapted photoreceptors, because the cytosolic  $Ca^{2+}$  level (500 nM) is higher than the  $Ca^{2+}$  dissociation constant for GCAP1 ( $K_d = 200$  nM [23]). The  $Ca^{2+}$ -bound GCAP1 crystal structure is known [24] and  $Ca^{2+}$ -bound GCAP1 forms a dimer in solution [25,26]. However, the dimeric GCAP1 structure in solution may be an artifact of the high protein concentrations used for NMR and EPR [25], because GCAP1 is monomeric under physiological conditions [27]. Also, a mutation in GCAP5 (R22A) that abolishes GCAP5 dimerization also causes a 3-fold higher activation of RetGC [28], implying the GCAP5 dimerization is not essential for cyclase activation. In our model (Figure 1B), GCAP1 is proposed to bind to RetGC at the junction between the kinase homology domain

(KHD) and the dimerization domain (DD). The model suggests that a  $\text{Ca}^{2+}$ -induced change in RetGC tertiary structure near the KHD/DD junction (caused by  $\text{Ca}^{2+}$  binding to GCAP1) could alter the quaternary structure of DD and perturb the dimer interface of the RetGC catalytic domain, causing a modulation in catalytic activity (Figure 1B). In essence, GCAP1 binding to RetGC1 is proposed to cause a scissoring-like motion of the helices in the DD (red coiled-coil in figure 1B) that modulates the quaternary structure of the catalytic subunits (akin to the T  $\rightarrow$  R transition for hemoglobin [29]). I propose that  $\text{Ca}^{2+}$ -free GCAP1 binding to RetGC1 may rigidify the coiled-coil and cause it to adopt a conformation that connects the two catalytic subunits to achieve maximal catalytic activity at low  $\text{Ca}^{2+}$  levels (Figure 1B, middle). By contrast, the binding of  $\text{Ca}^{2+}$ -bound GCAP1 to RetGC1 is predicted to increase the interhelical angle in the DD (red coiled coil), which may disrupt the connection between the catalytic subunits, causing the catalytic activity to turn off at high  $\text{Ca}^{2+}$  levels (Figure 1B, right panel). This model also accounts for the low catalytic activity in the absence of GCAP1, because the RetGC dimerization domain is less restrained (scissoring-like motion, double-headed arrows in figure 1B, left) and only transiently adopts the optimal conformation required for cyclase activation. Therefore, the absence of GCAP1 gives rise to conformational heterogeneity that causes lower catalytic activity (see double-headed arrows in figure 1B, left panel).

Mutations in GCAP1 (G86R, Y99C, I143N) [14-16,20,30] that weaken  $\text{Ca}^{2+}$  binding also abolish the  $\text{Ca}^{2+}$ -dependent activation of RetGC that causes autosomal dominant cone dystrophy. The weaker  $\text{Ca}^{2+}$  binding affinity of the GCAP1 disease mutants (G86R, Y99C, I143N) allows the  $\text{Ca}^{2+}$ -free GCAP1 to persist even at high  $\text{Ca}^{2+}$  levels in the dark, which causes constitutive activation of RetGC. In particular, the Y99C mutation in GCAP1 (that weakens  $\text{Ca}^{2+}$  binding to the third EF-hand in GCAP1) causes the  $\text{Ca}^{2+}$ -free mutant to constitutively activate RetGC that in turn leads to elevated levels of cGMP, which causes retinal degeneration [16,31]. Future studies are needed to solve atomic-resolution structures of RetGC bound to GCAP1 to test the model in figure 1B.

### Conclusion

GCAP1 binding to RetGC is essential for  $\text{Ca}^{2+}$ -dependent regulation of photoreceptor cyclase activity that dynamically controls the level of cGMP required for visual phototransduction.  $\text{Ca}^{2+}$ -bound GCAP1 inhibits RetGC at high  $\text{Ca}^{2+}$  levels in dark-adapted photoreceptors. Light activation of retinal photoreceptors leads to a drop in the cytosolic  $\text{Ca}^{2+}$  concentration that in turn causes  $\text{Ca}^{2+}$ -free GCAP1 to activate RetGC to replenish the cGMP concentration during visual recovery. GCAP1 Mutations (G86R, Y99C, I143N) that weaken  $\text{Ca}^{2+}$  binding also cause constitutive activation of RetGC, which causes retinal degenerative diseases. A structural model was presented to understand the structural basis of the GCAP1 binding interaction with RetGC, which suggests the central dimerization domain allosterically couples the GCAP1 binding site (in KHD) with the catalytic domain.

### Bibliography

1. Stryer L. "Visual excitation and recovery". *Journal of Biological Chemistry* 266.17 (1991): 10711-10714.
2. Arshavsky VY, *et al.* "G proteins and phototransduction". *Annual Review of Physiology* 64 (2002): 153-187.
3. Arshavsky VY and ME Burns. "Current understanding of signal amplification in phototransduction". *Cellular Logistics* 4 (2014): e29390.
4. Koch KW and D Dell'Orco. "Protein and signaling networks in vertebrate photoreceptor cells". *Frontiers in Molecular Neuroscience* 8 (2015): 67.
5. Pugh EN, *et al.* "Molecular mechanisms of vertebrate photoreceptor light adaptation". *Current Opinion in Neurobiology* 9.4 (1999): 410-418.
6. Palczewski K, *et al.* " $\text{Ca}^{2+}$ -binding proteins in the retina: structure, function, and the etiology of human visual diseases". *Bioessays* 22.4 (2000): 337-350.

7. Dizhoor AM, *et al.* "Mg<sup>2+</sup>/Ca<sup>2+</sup> cation binding cycle of guanylyl cyclase activating proteins (GCAPs): role in regulation of photoreceptor guanylyl cyclase". *Molecular and Cellular Biochemistry* 334.1-2 (2010): 117-124.
8. Koch KW and L Stryer. "Highly cooperative feedback control of retinal rod guanylate cyclase by calcium ions". *Nature* 334.6177 (1988): 64-66.
9. Lim S, *et al.* "Structural diversity of neuronal calcium sensor proteins and insights for activation of retinal guanylyl cyclase by GCAP1". *Frontiers in Molecular Neuroscience* 7 (2014): 19.
10. Palczewski K, *et al.* "Molecular cloning and characterization of retinal photoreceptor guanylyl cyclase-activating protein". *Neuron* 13.2 (1994): 395-404.
11. Peshenko IV and AM Dizhoor. "Guanylyl cyclase-activating proteins (GCAPs) are Ca<sup>2+</sup>/Mg<sup>2+</sup> sensors: implications for photoreceptor guanylyl cyclase (RetGC) regulation in mammalian photoreceptors". *Journal of Biological Chemistry* 279.17 (2004): 16903-16906.
12. Dizhoor AM and JB Hurley. "Regulation of photoreceptor membrane guanylyl cyclases by guanylyl cyclase activator proteins". *Methods* 19.4 (1999): 521-531.
13. Mendez A, *et al.* "Role of guanylate cyclase-activating proteins (GCAPs) in setting the flash sensitivity of rod photoreceptors". *Proceedings of the National Academy of Sciences of the United States of America* 98.17 (2001): 9948-9953.
14. Downes SM, *et al.* "Autosomal dominant cone and cone-rod dystrophy with mutations in the guanylate cyclase activator 1A gene-encoding guanylate cyclase activating protein-1". *Archives of Ophthalmology* 119.1 (2001): 96-105.
15. Jiang L and W Baehr. "GCAP1 mutations associated with autosomal dominant cone dystrophy". *Advances in Experimental Medicine and Biology* 664 (2010): 273-282.
16. Payne AM, *et al.* "A mutation in guanylate cyclase activator 1A (GUCA1A) in an autosomal dominant cone dystrophy pedigree mapping to a new locus on chromosome 6p21.1". *Human Molecular Genetics* 7.2 (1998): 273-277.
17. Bondarenko VA, *et al.* "Involvement of rhodopsin and ATP in the activation of membranous guanylate cyclase in retinal photoreceptor outer segments (ROS-GC) by GC-activating proteins (GCAPs): a new model for ROS-GC activation and its link to retinal diseases". *Molecular and Cellular Biochemistry* 334.1-2 (2010): 125-139.
18. Wilkie SE, *et al.* "Functional characterization of missense mutations at codon 838 in retinal guanylate cyclase correlates with disease severity in patients with autosomal dominant cone-rod dystrophy". *Human Molecular Genetics* 9.20 (2000): 3065-3073.
19. Baehr W and K Palczewski. "Guanylate cyclase-activating proteins and retina disease". *Subcellular Biochemistry* 45 (2007): 71-91.
20. Behnen P, *et al.* "Involvement of the calcium sensor GCAP1 in hereditary cone dystrophies". *Biological Chemistry* 391.6 (2010): 631-637.
21. Dizhoor AM, *et al.* "Constitutive activation of photoreceptor guanylate cyclase by Y99C mutant of GCAP-1. Possible role in causing human autosomal dominant cone degeneration". *Journal of Biological Chemistry* 273.28 (1998): 17311-17314.
22. Newbold RJ, *et al.* "Guanylate cyclase activating proteins, guanylate cyclase and disease". *Advances in Experimental Medicine and Biology* 514 (2002): 411-438.
23. Lim S, *et al.* "Effects of Ca<sup>2+</sup>, Mg<sup>2+</sup>, and myristoylation on guanylyl cyclase activating protein 1 structure and stability". *Biochemistry* 48.5 (2009): 850-862.
24. Stephen R, *et al.* "Stabilizing function for myristoyl group revealed by the crystal structure of a neuronal calcium sensor, guanylate cyclase-activating protein 1". *Structure* 15.11 (2007): 1392-1402.

25. Lim S., *et al.* "Retinal guanylyl cyclase activating protein 1 forms a functional dimer". *PLoS ONE* 13.3 (2018): e0193947.
26. Ames JB. "Dimerization of neuronal calcium sensor proteins". *Frontiers in Molecular Neuroscience* 11 (2018): 397.
27. Boni F., *et al.* "Modulation of guanylate cyclase activating protein 1 (GCAP1) dimeric assembly by Ca(2+) or Mg(2+): hints to understand protein activity". *Biomolecules* 10.10 (2020): 1408.
28. Cudia, D., *et al.* "NMR and EPR-DEER structure of a dimeric guanylate cyclase activator protein-5 from zebrafish photoreceptors". *Biochemistry* 60.41 (2021): 3058-3070.
29. Monod J., *et al.* "On the nature of allosteric transitions: a plausible model". *Journal of Molecular Biology* 12.1 (1965): 88-118.
30. Buch PK., *et al.* "Dominant cone-rod dystrophy: a mouse model generated by gene targeting of the GCAP1/Guca1a gene". *PLoS ONE* 6.3 (2011): e18089.
31. Sokal I., *et al.* "GCAP1 (Y99C) mutant is constitutively active in autosomal dominant cone dystrophy". *Molecular Cell* 2.1 (1998): 129-133.

**Volume 14 Issue 12 December 2023**

**©All rights reserved by James B Ames.**